Saturday 17 October 2026
Export KIDS’s income statement to Excel — free account
OrthoPediatrics Corp.
KIDS Healthcare Medical Devices
OrthoPediatrics Corp.’s revenue for fiscal 2025 (year ended December 2025) was $236.3 million, up 15.4% from fiscal 2024. In the quarter to June 2026, revenue grew 15.4%, EPS was flat, free cash flow grew 77.6% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years.
21.95
0.62
−2.75%
Follow KIDS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.92 | 1.76 | 1.54 | 1.82 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(751.60) | 40.26 | (114.35) | 495.75 | |
P/B ratio |
1.25 | 1.20 | 1.11 | 1.34 | |
Price to Tangible BV |
2.62 | 2.61 | 2.56 | 3.10 | |
EV/Sales |
2.08 | 1.91 | 1.74 | 2.02 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(24.69) | (92.94) | (106.07) | 68.81 | |
EV/FCF |
(15.02) | (24.95) | (28.67) | (129.34) | |
Quick Ratio |
3.34 | 2.53 | 2.23 | 2.06 | |
Current Ratio |
7.40 | 5.55 | 5.21 | 4.78 | |
Net Debt/EBITDA |
1,091.12 | (154.81) | (17.79) | 30.33 | |
Debt/Assets |
19.63% | 19.10% | 19.39% | 19.09% | |
Debt/Equity |
0.28 | 0.28 | 0.29 | 0.28 | |
Asset Turnover |
0.46 | 0.48 | 0.50 | 0.50 | |
Operating CF/Net income |
0.05 | (1.02) | 0.31 | (0.13) | |
Capex/Depreciation |
(0.30) | (0.08) | (0.31) | (0.71) | |
Interest Coverage |
(5.17) | (4.23) | (3.97) | (1.61) | |
Research and Development Expense of Revenue |
3.81% | 3.67% | 3.76% | 3.30% | |
Selling, General and Administrative Expense of Revenue |
78.05% | 78.49% | 83.38% | 76.74% | |
Intangible Assets out of Total Assets |
0.37 | 0.37 | 0.38 | 0.38 | |
Share Based Compensation of Revenue |
6.94% | 7.17% | 6.71% | 5.94% | |
Graham Net Nets |
0.23 | 0.23 | 0.22 | 0.18 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(10.52%) | (9.52%) | (10.59%) | (8.78%) | |
Free Cash Flow Yield |
(7.22%) | (4.34%) | (3.92%) | (0.86%) | |
Revenue per Share |
2.60 | 2.63 | 2.51 | 2.93 | |
Operating CF per Share |
(0.02) | 0.44 | (0.14) | 0.04 | |
Capex per Share |
(0.12) | (0.03) | (0.07) | (0.17) | |
Free Cash Flow per Share |
(0.15) | 0.42 | (0.21) | (0.13) | |
Cash per Share |
2.54 | 2.68 | 2.15 | 1.99 | |
Shareholders Equity per Share |
14.82 | 14.77 | 14.30 | 14.29 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
14.82 | 14.77 | 14.30 | 14.29 | |
Free Cash Flow |
(3.42) | 9.75 | (5.05) | (3.12) | |
Working Capital |
212.62 | 210.22 | 198.68 | 199.66 | |
Capital Expenditures |
(2.84) | (0.60) | (1.76) | (4.04) | |
Net Current Asset Value |
101.68 | 94.39 | 82.39 | 84.73 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.05 | 0.01 | 0.03 | 0.06 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
47.05 | 48.10 | 49.21 | 57.37 | |
Average Payables |
9.41 | 13.85 | 16.95 | 17.46 | |
Average Inventory |
124.87 | 125.40 | 126.89 | 131.42 | |
Average Assets |
491.39 | 490.92 | 486.22 | 507.50 | |
Average Common Equity |
360.11 | 350.58 | 342.93 | 349.56 |
Columns are period end dates